Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry-Reference-Cited by-同舟云学术

Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry

Published:2018-06 Issue:6 Volume:66 Page:920-925
ISSN:0277-2116
Container-title:Journal of Pediatric Gastroenterology & Nutrition
language:en
Short-container-title:

Author:

Aloi Marina,Bramuzzo Matteo,Arrigo Serena,Romano Claudio,D’Arcangelo Giulia,Lacorte Doriana,Gatti Simona,Illiceto Maria T.,Zucconi Francesca,Dilillo Dario,Zuin Giovanna,Knafelz Daniela,Ravelli Alberto,Cucchiara Salvatore,Alvisi Patrizia

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Pediatrics, Perinatology and Child Health

Reference43 articles.

1. Ulcerative colitis;Ungaro;Lancet,2017

2. Inflammatory bowel disease: cause and immunobiology;Baumgart;Lancet,2007

3. The role of TNFalpha in ulcerative colitis;Sands;J Clin Pharmacol,2007

4. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005

5. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis;Hyams;Clin Gastroenterol Hepatol,2012

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort;Journal of Pediatric Gastroenterology & Nutrition;2023-02-19

2. Natural History of Ulcerative Colitis in Children;Pediatric Inflammatory Bowel Disease;2023

3. Anti-TNF Therapies Other Than Infliximab for the Treatment of Pediatric Inflammatory Bowel Disease;Pediatric Inflammatory Bowel Disease;2023

4. A critical review of adalimumab for the treatment of moderate-to-severe active ulcerative colitis in children;Expert Review of Gastroenterology & Hepatology;2022-11-21

5. Infliximab Can Be Effective in Pediatric Patients with Ulcerative Colitis and Primary Failure of Adalimumab;ANN CLIN LAB SCI;2022